Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. An experimental drug being developed to treat Parkinson's disease psychosis and schizophrenia.

Etymologies

Sorry, no etymologies found.

Examples

  • ACADIA is developing a portfolio consisting of four product candidates including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail.

    Business Wire Travel News

  • "The first half of 2010 was focused on executing our broad development strategy designed to leverage the potential of pimavanserin over a range of neurological and psychiatric indications with large unmet medical needs together with our collaborative partner, Biovail"

    Business Wire Travel News

  • In addition to pimavanserin, ACADIA has a product candidate in Phase II development for chronic pain and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha.

    Business Wire Travel News

  • The decrease in external service costs was primarily attributable to lower clinical costs incurred on ACADIA's Phase III program with pimavanserin for

    Business Wire Travel News

  • "The first half of 2010 was focused on executing our broad development strategy designed to leverage the potential of pimavanserin over a range of neurological and psychiatric indications with large unmet medical needs together with our collaborative partner, Biovail," said Uli Hacksell, Ph. D.,

    Business Wire Travel News

  • Included in this amount, is a portion of the expenses associated with the new Phase 3 trials for pimavanserin in (1) Parkinson's disease pyschosis, which is expected to begin in the second quarter of 2010 and to cost a total of $10 million to $15 million, and (2) in schizophrenia, as adjunct therapy, which is expected to begin mid-2010 and to cost a total of $30 million to $40 million.

    THE MEDICAL NEWS

  • Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinso ...

    THE MEDICAL NEWS

  • Biovail provides update on its Phase III program with pimavanserin for Parkinson's disease psychosis

    THE MEDICAL NEWS

  • Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

    THE MEDICAL NEWS

  • Biovail will assume all costs associated with the development, manufacturing, and commercialization of pimavanserin in all indications save specified ongoing studies, which Acadia will fund.

    GEN News Highlights

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.